A new study reveals that a simple blood test can identify women at high risk of developing dementia up to 25 years before symptoms appear. This breakthrough offers a crucial window for preventative measures, early support, and deeper research into the disease’s progression.
Identifying Early Biomarkers
Researchers analyzed blood samples from 2,766 cognitively healthy women aged 65 to 79, tracking their cognitive function over decades. The focus was on a protein fragment called plasma phosphorylated tau 217 (p-tau217). Elevated levels of this protein correlate with the tau protein tangles found in the brains of Alzheimer’s and dementia patients.
Why this matters: Early detection is vital because current treatments are more effective when started before significant brain damage occurs. Identifying high-risk individuals allows for timely intervention, including lifestyle changes, experimental therapies, and closer monitoring.
Key Findings and Accessibility
The study confirms a strong link between higher p-tau217 levels and the future development of mild cognitive impairment (MCI) and dementia. While the test isn’t foolproof, it offers a significantly less invasive and more accessible alternative to brain scans or spinal fluid tests.
“Blood-based biomarkers… are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” notes neuroscientist Linda McEvoy.
The unusually long 25-year follow-up period provides robust data, further solidifying p-tau217 as a reliable biomarker.
Hormone Therapy and Racial Differences
The study also explored how hormone therapy and race affect biomarker accuracy. High p-tau217 levels predicted dementia in women who had taken both estrogen and progestin but not estrogen alone. For MCI, hormone usage showed no clear link.
Notably, the association between high p-tau217 and dementia held true for both White and Black women. However, no correlation was found between high p-tau217 levels and MCI in Black women, suggesting possible misdiagnosis or differing contributing factors.
Future Implications
Although not yet ready for widespread screening, the research strengthens the case for blood-based p-tau217 testing as a proactive tool for identifying at-risk individuals. Further studies are needed to refine the test and understand why some with high p-tau217 levels do not develop dementia.
“Our study suggests we may be able to identify women at elevated risk for dementia decades before symptoms emerge,” says epidemiologist Aladdin Shadyab, opening the door for earlier prevention and more targeted monitoring.
This research is a critical step toward understanding and potentially halting the progression of Alzheimer’s and dementia, offering hope for earlier intervention and improved patient outcomes.
